top
Search terms
Results 1 - 3 of 3 - ordered by :
Ehjournal

Treatment with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce low density lipoprotein cholesterol (LDL-C) by approximately 4560%, whether used alone or in combination with a ...

European Heart Journal, Ference, Brian A, Cannon, Christopher P, Landmesser, Ulf, Lüscher, Thomas F, Catapano, Alberico L, Ray, Kausik K

Date : 14/07/2018 Item size : 234877 bytes
Ehjournal

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSThe Task Force for dual antiplatelet therapy in coronary artery disease of the ...

European Heart Journal, Valgimigli, Marco, Bueno, Héctor, Byrne, Robert A, Collet, Jean-Philippe, Costa, Francesco, Jeppsson, Anders, Jüni, Peter, Kastrati, Adnan, Kolh, Philippe, Mauri, Laura, ...

Date : 14/01/2018 Item size : 1544322 bytes
Ehjournal

Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are ...

European Heart Journal, Ference, Brian A., Ginsberg, Henry N., Graham, Ian, Ray, Kausik K., Packard, Chris J., Bruckert, Eric, Hegele, Robert A., Krauss, Ronald M., Raal, Frederick J., Schunkert, ...

Date : 21/08/2017 Item size : 592220 bytes